Format

Send to

Choose Destination
Cell Metab. 2018 Sep 4;28(3):400-414.e8. doi: 10.1016/j.cmet.2018.06.011. Epub 2018 Jul 12.

Mitofusin 2 Regulates Axonal Transport of Calpastatin to Prevent Neuromuscular Synaptic Elimination in Skeletal Muscles.

Author information

1
Department of Pathology, Case Western Reserve University, Cleveland, OH, USA.
2
Electron Microscopy Core Facility, Case Western Reserve University, Cleveland, OH, USA.
3
Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH, USA.
4
College of Sciences, University of Texas at San Antonio, San Antonio, TX, USA.
5
Department of Pharmacology, Case Western Reserve University, Cleveland, OH, USA.
6
Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
7
Department of Pathology, Case Western Reserve University, Cleveland, OH, USA; Department of Pharmacology, Case Western Reserve University, Cleveland, OH, USA. Electronic address: xinglong.wang@case.edu.

Abstract

Skeletal muscles undergo atrophy in response to diseases and aging. Here we report that mitofusin 2 (Mfn2) acts as a dominant suppressor of neuromuscular synaptic loss to preserve skeletal muscles. Mfn2 is reduced in spinal cords of transgenic SOD1G93A and aged mice. Through preserving neuromuscular synapses, increasing neuronal Mfn2 prevents skeletal muscle wasting in both SOD1G93A and aged mice, whereas deletion of neuronal Mfn2 produces neuromuscular synaptic dysfunction and skeletal muscle atrophy. Neuromuscular synaptic loss after sciatic nerve transection can also be alleviated by Mfn2. Mfn2 coexists with calpastatin largely in mitochondria-associated membranes (MAMs) to regulate its axonal transport. Genetic inactivation of calpastatin abolishes Mfn2-mediated protection of neuromuscular synapses. Our results suggest that, as a potential key component of a novel and heretofore unrecognized mechanism of cytoplasmic protein transport, Mfn2 may play a general role in preserving neuromuscular synapses and serve as a common therapeutic target for skeletal muscle atrophy.

KEYWORDS:

Mfn2; amyotrophic lateral sclerosis; axonal transport; calpastatin; mitochondria; mitochondria-associated membranes; nerve injury; neuromuscular synapse; sarcopenia; skeletal muscle atrophy

PMID:
30017354
PMCID:
PMC6125186
[Available on 2019-09-04]
DOI:
10.1016/j.cmet.2018.06.011

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center